Related Experiment Video
Updated: May 17, 2026

Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.
Published on: February 15, 2019
Inhibition of Aeromonas sobria serine protease (ASP) by α2-macroglobulin
Yoji Murakami1, Yoshihiro Wada, Hidetomo Kobayashi
1Department of Urology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Kumamoto 860-8556, Japan.
Abstract:
ASP is a serine protease secreted by Aeromonas sobria. ASP cleaves various plasma proteins, which is associated with onset of sepsis complications, such as shock and blood coagulation disorder. To investigate a host defense mechanism against this virulence factor, we examined the plasma for ASP inhibitor(s). Human plasma inhibited ASP activity for azocasein, which was almost completely abolished by treating plasma with methylamine, which inactivates α2-macroglobulin (α2-MG). The ASP-inhibitor complex in ASP-added plasma was not detected by immunoblotting using anti-ASP antibody; however, using gel filtration of the plasma ASP activity for an oligopeptide, the ASP substrate was eluted in the void fraction (Mw>200 000), suggesting ASP trapping by α2-MG. Indeed, human α2-MG inhibited ASP azocaseinolytic activity in a dose-dependent manner, rapidly forming a complex with the ASP. Fibrinogen degradation by ASP was completely inhibited in the presence of α2-MG. α1-Protease inhibitor, antithrombin, and α2-plasmin inhibitor neither inhibited ASP activity nor formed a complex with ASP. Surprisingly, ASP degraded these plasma serine protease inhibitors. Thus, α2-MG is the major ASP inhibitor in the human plasma and can limit ASP virulence activities in A. sobria infection sites. However, as shown by fluorescence correlation spectroscopy, slow ASP inhibition by α2-MG in plasma may indicate insufficient ASP control in vivo.
Insights
Human plasma contains alpha2-macroglobulin (α2-MG), a key inhibitor of Aeromonas sobria serine protease (ASP). While α2-MG neutralizes ASP, its slow inhibition may limit effectiveness in sepsis.
Area of Science:
- Biochemistry
- Immunology
- Microbiology
Background:
- Aeromonas sobria serine protease (ASP) causes sepsis complications by cleaving plasma proteins.
- Host defense mechanisms against ASP are not fully understood.
Purpose of the Study:
- Identify inhibitors of ASP in human plasma.
- Characterize the interaction between ASP and identified inhibitors.
Main Methods:
- Azocaseinolytic activity assays.
- Methylamine treatment to inactivate α2-macroglobulin (α2-MG).
- Gel filtration and immunoblotting to detect ASP-inhibitor complexes.
- Fibrinogen degradation assays.
- Fluorescence correlation spectroscopy.
Main Results:
- Human plasma inhibited ASP activity, primarily via α2-MG.
- α2-MG dose-dependently inhibited ASP activity and formed complexes.
- α2-MG prevented fibrinogen degradation by ASP.
- ASP degraded other plasma serine protease inhibitors (α1-PI, AT, α2-PI).
- Slow ASP inhibition by α2-MG observed via fluorescence correlation spectroscopy.
Conclusions:
- α2-macroglobulin is the major human plasma inhibitor of ASP.
- α2-MG can limit ASP virulence in Aeromonas sobria infections.
- The slow inhibition rate of ASP by α2-MG may compromise in vivo control.
Related Concept Videos
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Inhibitors of Bacterial Protein Synthesis
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Enzyme Inhibition
Clinical Significance of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing

